References
- Itoh H, Komori K, Onohara T, Funahashi S, Okadome K, Sugimachi K. Late graft failure of autologous vein grafts for arterial occlusive disease: clinical and experimental studies. Surg Today 1995;25:293-8. https://doi.org/10.1007/BF00311249
- Steele PM, Chesebro JH, Stanson AW, et al. Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. Circ Res 1985;57:105-12. https://doi.org/10.1161/01.RES.57.1.105
- Glagov S. Intimal hyperplasia, vascular modeling, and the restenosis problem. Circulation 1994;89:2888-91. https://doi.org/10.1161/01.CIR.89.6.2888
- Autieri MV, Yue TL, Ferstein GZ, Ohlstein E. Antisense oligonucleotides to the p65 subunit of NF-kB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem Biophys Res Commun 1995;213:827-36. https://doi.org/10.1006/bbrc.1995.2204
- Zingarelli B, Sheehan M, Wong HR. Nuclear factor-kappaB as a therapeutic target in critical care medicine. Crit Care Med 2003;31(1 Suppl):S105-11. https://doi.org/10.1097/00003246-200301001-00015
- Martindale JL, Holbrook NJ. Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002;192:1-15. https://doi.org/10.1002/jcp.10119
- Elliott PJ, Ross JS. The proteasome: a new target for novel drug therapies. Am J Clin Pathol 2001;116:637-46. https://doi.org/10.1309/44HW-5YCJ-FLLP-3R56
- Yeh ET. Ubiquitin, proteasome, and restenosis: a brave new world for cardiovascular research. Circulation 2002;105:408-10.
- Bu DX, Erl W, de Martin R, Hansson GK, Yan ZQ. IKKbeta-dependent NF-kappaB pathway controls vascular inflammation and intimal hyperplasia. FASEB J 2005;19:1293-5. https://doi.org/10.1096/fj.04-2645fje
- Fernandez Y, Miller TP, Denoyelle C, et al. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem 2006;281:1107-18. https://doi.org/10.1074/jbc.M511607200
- Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin. Lab Invest 1985;52:611-6.
- Tulis DA, Durante W, Liu X, Evans AJ, Peyton KJ, Schafer AI. Adenovirusmediated heme oxygenase-1 gene delivery inhibits injury-induced vascular neointima formation. Circulation 2001;104:2710-5. https://doi.org/10.1161/hc4701.099585
- Bohorquez M, Koch C, Trygstad T, Pandit N. A Study of the Temperature- Dependent Micellization of Pluronic F127. J Colloid Interface Sci 1999;216:34-40. https://doi.org/10.1006/jcis.1999.6273
- Zahradka P, Werner JP, Buhay S, Litchie B, Helwer G, Thomas S. NF-kappaB activation is essential for angiotensin II-dependent proliferation and migration of vascular smooth muscle cells. J Mol Cell Cardiol 2002;34:1609-21. https://doi.org/10.1006/jmcc.2002.2111
- Pollman MJ, Hall JL, Gibbons GH. Determinants of vascular smooth muscle cell apoptosis after balloon angioplasty injury. Influence of redox state and cell phenotype. Circ Res 1999;84:113-21. https://doi.org/10.1161/01.RES.84.1.113
- Azevedo LC, Pedro MA, Souza LC, et al. Oxidative stress as a signaling mechanism of the vascular response to injury: the redox hypothesis of restenosis. Cardiovasc Res 2000;47:436-45. https://doi.org/10.1016/S0008-6363(00)00091-2
- Hussein MA. Pharmacotherapy of multiple myeloma. Expert Opin Pharmacother 2006;7:767-81. https://doi.org/10.1517/14656566.7.6.767
- Pekol T, Daniels JS, Labutti J, et al. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos 2005;33:771-7. https://doi.org/10.1124/dmd.104.002956
- Jackson G, Einsele H, Moreau P, Miguel JS. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev 2005;31:591-602. https://doi.org/10.1016/j.ctrv.2005.10.001
- Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98. https://doi.org/10.1056/NEJMoa043445
- Henninger N, Sicard KM, Bouley J, Fisher M, Stagliano NE. The proteasome inhibitor VELCADE reduces infarction in rat models of focal cerebral ischemia. Neurosci Lett 2006;398:300-5. https://doi.org/10.1016/j.neulet.2006.01.015
- Kim DW, Kwon JS, Kim YG, et al. Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model. Circulation 2004;109:1558-63. https://doi.org/10.1161/01.CIR.0000124063.74526.BE
- Sinn DI, Lee ST, Chu K, et al. Proteasomal inhibition in intracerebral hemorrhage: neuroprotective and anti-inflammatory effects of bortezomib. Neurosci Res 2007;58:12-8. https://doi.org/10.1016/j.neures.2007.01.006
- Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology (Williston Park) 2004;18(14 Suppl 11):14-21.
- Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med (Berl) 2003;81:235-45. https://doi.org/10.1007/s00109-003-0422-2
- He XP, Li XX, Bi YW, et al. The proteasome inhibitor bortezomib inhibits intimal hyperplasia of autologous vein grafting in rat model. Transplant Proc 2008;40:1722-6. https://doi.org/10.1016/j.transproceed.2008.01.063